You seem to be forgetting that Brilacidin is a new

You seem to be forgetting that Brilacidin is a new class of medicine and not subject to the same rules as were antibiotics in the past. The prior classes of antibiotics allowed viruses to build up resistance, but with the new methods of attacking the infection or virus (popping the envelope) the odds for them being able to build up a resistance to Brilacidin is light years less likely.

That is also why Brilacidin as an antibiotic should be used so much more liberally in infectious situations and become a much higher revenue generating antibiotic as those of the past as the strongest were reserved for only the most severe cases due to resistance worries.

Brilacidin for humans is in small molecule form. For industrial purposes, it would be in the form of a polymer (strands of small molecules strung together and this could possibly lead to B being used in innumerable applications (textiles, plastics, paints, etc). Just as CV is a totally new arm of revenues for IPIX not envisioned prior to 2020, the industrial side could also prove to be a monstrous source of revenues and that could be addressed once the human indications have been hammered out a little more and revenues are streaming in to IPIX.

It is then evident that there is no way enough is known about the overall applications for Brilacidin in either human indications or commercial/industrial applications for Leo to be considering the entire platform at the current time. But I do feel that it would be best to give the entire platform to one BP as IMO there would be too great a chance for one licensee leaking into another's license rights and too much chance of major lawsuits. Give one BP the entire platform with a significant bonus having to be paid for such a right and then have a scaled royalty basis so that IPIX gets continually higher royalties as total sales increases for Brilacidin. Win/win for both BP and IPIX IMO.